ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA <500000 Copies/mL-Reference-Cited by-同舟云学术

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA <500000 Copies/mL

Published:2017-12-14 Issue:11 Volume:66 Page:1689-1697
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Taiwo Babafemi O¹,Zheng Lu²,Stefanescu Andrei³,Nyaku Amesika⁴,Bezins Baiba¹,Wallis Carole L⁵,Godfrey Catherine⁶,Sax Paul E⁷,Acosta Edward⁸,Haas David⁹,Smith Kimberly Y¹⁰,Sha Beverly¹¹,Van Dam Cornelius¹²,Gulick Roy M¹³

Affiliation:

1. Division of Infectious Diseases and Center for Global Health, Northwestern University, Chicago, Illinois

2. Department of Biostatistics

3. Statistical Data Management Center, Harvard T H Chan School of Public Health, Boston, Massachusetts

4. Division of Infectious Diseases, Rutgers University, New Brunswick, New Jersey

5. BARC South Africa and Lancet Laboratories, Johannesburg, South Africa

6. Division of AIDS, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryl

7. Division of Infectious Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

8. Department of Pharmacology and Toxicology, University of Alabama, Birmingham

9. Department of Medicine, Vanderbilt University, Nashville, Tennessee

10. ViiV Healthcare, Research Triangle Park, North Carolina

11. Division of Infectious Diseases, Rush University, Chicago, Illinois

12. Regional Center for Infectious Diseases, Cone Health, Greensboro, North Carolina

13. Division of Infectious Diseases, Weill Cornell Medicine, New York, New York

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/66/11/1689/25084222/cix1083.pdf

Reference30 articles.

1. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults;Min;AIDS,2011

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments;Antiviral Research;2024-10

2. Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation;Viruses;2024-08-30

3. Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir;Viruses;2024-07-19

4. D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years;Contemporary Clinical Trials;2024-07

5. Long-acting HIV Treatments: Study Design, Logistics, and Access;Open Forum Infectious Diseases;2024-06-15